On page 5 of the article, in the last paragraph of the section "Prognostic genetic platforms: molecular phenotypes and translation to the clinic" a relevant discrepancy between the text and Table 1 could be misunderstood, therefore the paragraph was corrected. The corrected version as well as some changes in Tables 1 and 2 that reflect the updated modifications are shown here:
The 2017 update of the ASCO Clinical Practice Guideline of Biomarkers use for the adjuvant therapy of breast cancer, focused on the use of MammaPrint ® , specified that MammaPrint ® may be used in patients with HR+, HER2-negative cases with high clinical risk per MINDACT, either without lymph node involvement or with 1-3 positive nodes, to inform decisions on withholding adjuvant chemotherapy. However, the ASCO guideline warns that these patients should be informed that a benefit of chemotherapy cannot be excluded, particularly in patients with > 1 nodes involved. 
